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lithium was re-authorised. Unfortunately, it appeared his 
outpatient appointments had been subject to cancellations 
hence his lithium levels were not being regularly moni-
tored. Patient at time of report was being ventilated.”
This summary is based on a patient safety alert issued 
in December 2009 by the NPSA in collaboration with the 
Prescribing Observatory for Mental Health and the National 
Pharmacy Association to improve the safety of lithium 
therapy, with key actions for staff (www.nrls.npsa.nhs.uk/
resources/type/alerts/?entryid45=65426&p=1).5 
Problems identified by the National Patient Safety Agency
• Poor monitoring of lithium blood concentrations 
and complementary blood tests, with associated 
inadequate systems for supporting recommended 
biochemical monitoring of patients prescribed 
lithium and the prompt communication of test results 
across care settings.
• A failure to inform patients of recognised side effects 
and prepare them to be vigilant for signs of incipient 
lithium toxicity.
What can we do?
• The NPSA asked healthcare organisations to review 
their local systems for ensuring that blood test 
results are communicated between laboratories and 
prescribers. The NPSA has also provided practitioners 
with a standard patient information pack, which 
includes a patient held record book to track lithium 
serum concentrations and relevant clinical tests. 
• Individual practitioners who are monitoring patients 
taking lithium should:
-Issue repeat prescriptions only when they are 
satisfied that it is safe to do so, as informed by the 
serum lithium concentration and the results of 
biochemical monitoring
-Monitor serum lithium concentrations every three 
months, aiming for therapeutic concentrations 
(guidance range 0.6-1.0 mmol/l)3 at which side 
effects can be tolerated with no toxic effects (the box 
lists side effects of treatment and signs of toxicity). 
Higher concentrations may be required for younger 
patients with predominantly manic symptoms6
-Monitor older patients carefully for clinical features 
of toxicity (box), as they can experience toxicity even 
at the upper end of the guidance range7
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Following a Department of 
Health review in July 2010, the 
National Patient Safety Agency 
will be abolished and some of 
its functions transferred to a 
Patient Safety subcommittee 
of the new NHS Commissioning 
Board. Reports of incidents are, 
however, still encouraged at 
www.npsa.nhs.uk.
Why read this summary?
Lithium is a commonly prescribed drug for treating  bipolar 
disorder and unipolar (refractory) depression. Over 800 000 
prescriptions for lithium salts were dispensed in England 
in 2008.1
Lithium has a narrow therapeutic range and may be 
affected by changes in renal function and fluid balance 
(for example, when a person is dehydrated or pregnant).2 
Its tolerability profile also provides challenges for prescrib-
ing, as adverse effects such as fine tremor may be confused 
with the coarse tremor seen in toxicity. Lithium treatment 
increases the risk of clinical hypothyroidism and renal 
insufficiency (both acute and chronic). Thus tailoring doses 
for individual patients, with careful monitoring of lithium 
concentrations, estimated glomerular filtration rate, and 
thyroid stimulating hormone, is essential. 
Treatment is usually started by a psychiatrist, with longer 
term care and monitoring by a general practitioner, who 
can be guided by the relevant quality outcome framework 
(QOF) target for lithium monitoring in the general prac-
titioner contract. The 2006 guidelines from the National 
Institute for Health and Clinical Excellence (NICE) set out 
clear standards for lithium monitoring, including measure-
ment of serum lithium concentrations every three months 
and assessment of thyroid and renal function every six 
months.3 These guidelines are more stringent than the cur-
rent quality outcome framework targets for England.
A quality improvement programme showed that mental 
health trusts often do not have electronic systems that reli-
ably communicate test results between the laboratory and 
the clinical team or between primary and secondary care.4 
It also showed the shortcomings in the monitoring stand-
ards of QOF and NICE and a lack of understanding among 
patients of side effects and signs of toxicity.4
The National Patient Safety Agency (NPSA) received 
567 incident reports between October 2003 and Decem-
ber 2008 relating to poor lithium management, including 
two cases of severe harm where failures in monitoring led 
to lithium toxicity and admission to hospital in a critical 
condition. In addition, litigation data over the past 10 years 
show two deaths and 12 cases of severe harm, again where 
system failures in monitoring led to patient harms.
A typical incident report to the NPSA reads: “Emergency 
admission of patient for lithium toxicity in a critical con-
dition. Unfortunately his lithium levels were out of date. 
The last level was within the therapeutic range, hence his 
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approaches to shared care. Health services research to iden-
tify cost eff ective models of care and sharing of good practice 
would be welcome. 
 How will we know when practice has become safer? 
 Healthcare organisations were given until December 2010 
to implement the actions in this patient safety alert and are 
required to report compliance at that point. By 6 October 
2010, only a fi fth (70) of the 356 organisations required to 
take action had reported compliance to the Central Alerting 
Service. The NPSA will continue to monitor incidents reported 
by staff . The current quality improvement programme of lith-
ium monitoring will continue, with further clinical audits to 
measure performance against the standards noted above. 
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 -Monitor thyroid and renal function every six months 
and more often if renal function is impaired. If 
serum urea and creatinine concentrations become 
raised seek advice from a renal physician and/or 
psychiatrist as there are trade-off s between risks of 
renal impairment and unmanaged bipolar disorder 
 -Monitor patients carefully for clinical and 
biochemical evidence of hypothyroidism. Be 
especially vigilant for women starting lithium at age 
40-59 years, whose risk is much greater than the 
average risk for men (>20%  v 4.5%). 8 The clinical 
symptoms overlap with those of depression so can 
easily be missed 
 -Ask patients to use the lithium record book and 
explain its importance. The record book will be 
the key record for all the health professionals they 
encounter in diff erent settings, with up to date 
information on the type and dose of lithium they 
are taking, side eff ects they can expect, how these 
diff er from more serious signs of toxicity that they 
must look out for, and what may cause toxicity (box; 
record available at  www.nrls.npsa.nhs.uk/resources/
type/alerts/?entryid45=65426 ) 
 -Consider the potential for concomitant medication 
(such as angiotensin converting enzyme inhibitors; 
thiazides and related diuretics; and non-steroidal 
anti-infl ammatory drugs) to reduce the renal 
excretion of lithium and precipitate toxicity. Use of 
concomitant medication that may aff ect lithium 
therapy should be accompanied by more frequent 
monitoring of the serum lithium concentration.  
 Further details are given in the NICE guidelines 3 and see 
fi gure. 
 What else do we need to know? 
 In developing the patient safety alert, the NPSA was aware 
of variation in the prescribing and monitoring of lithium 
treatment across primary and secondary care, with diff erent 
 Main expected side effects of lithium treatment and key clinical 
features of toxicity 
 Expected side effects of lithium  
•  Fine tremor 
•  Dry mouth 
•  Altered taste sensation 
•  Increased thirst 
•  Increased frequency of urination 
•  Mild nausea 
•  Weight gain 
 Key features of lithium toxicity 
•  Vomiting or diarrhoea 
•  Coarse tremor (larger movements, 
especially of hands) 
•  Muscle weakness 
•  General lack of coordination, including ataxia 
•  Slurred speech 
•  Blurred vision 
•  Lethargy 
•  Confusion 
•  Seizures 
National Patient Safety Agency’s information booklet for patients taking lithium: front 
cover plus section 7. The whole booklet is available from  www.nrls.npsa.nhs.uk/resources/
type/alerts/?entryid45=65426 
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Primary HIV infection encompasses the biological and 
clinical manifestations of the period between initial 
contact with the virus and the appearance of specifi c 
antibodies.1
Why is primary HIV infection missed?
Primary HIV infection is symptomatic in most individu-
als but is easy to miss.3 4  In a cohort study of 46 patients 
with primary HIV infection, only a quarter of those with 
acute presentations caused by primary HIV infection 
were correctly diagnosed in various acute and primary 
care settings in the United States.5 The diagnosis of pri-
mary HIV infection was also missed at initial presenta-
tion in 19 of 40 patients (48%) in the United Kingdom.3 
The infection may be missed because the symptoms are 
transient, often lasting less than two weeks, and tend 
to overlap with those of infections that are much more 
common in clinical practice. Failure to elicit a history 
of exposure to the virus, reluctance to test, and lack of 
awareness of the limitations of testing in the acute phase 
may also contribute to diagnostic delay.3 4
Why does this matter?
The diagnosis of primary HIV infection has individual 
and public health benefi ts. If the infection is not recog-
nised, a clinically silent phase follows, during which 
CD4 T lymphocyte counts gradually decline.1 Early 
diagnosis allows monitoring for the onset of immuno-
defi ciency and timely institution of highly active antiret-
roviral treatment. Late diagnosis is associated with HIV 
related morbidity and mortality and adds to the cost of 
treatment.6 Patients with primary HIV infection have 
high levels of viraemia and are more likely to trans-
mit the infection by sexual contact.1 Counselling may 
thus reduce sexual risk behaviours and transmission 
of  infection.7
How is it diagnosed?
Clinical features
Fever is the most common symptom, present in 80-90% 
of patients. It typically appears two to four weeks after 
the infection and is commonly associated with sore 
throat and cervical lymphadenopathy. This may lead 
to the erroneous diagnosis of mononucleosis or ton-
sillitis.5 A non-specific maculopapular rash is seen in 
over 40% of patients but may be difficult to detect in 
patients with darkly pigmented skin.1 Headache may 
be present in over 50% of patients and may suggest 
HIV invasion of the central nervous system, an early 
event in the natural course of the infection.5 Primary 
HIV infection must be included in the differential diag-
nosis of patients presenting with aseptic meningitis.8 
Diagnosis is easier if the patient volunteers the 
information of possible exposure to HIV or is known to 
belong to a high risk group for the disease. Disclosing 
this information may, however, be difficult both for the 
patient and the doctor (case scenario) owing to the need 
to probe into the sensitive issues, such as high risk sex-
ual behaviour and substance misuse. These difficulties 
can be magnified when clinical contact is occasional 
and there is little time to forge a close doctor-patient 
relationship. If a patient refuses a test, explore the rea-
sons for this and correct any inaccurate beliefs about 
infection or the consequences of testing; document the 
patient’s reasons for declining the test.9
In developed countries, men having sex with men 
represent the category most at risk of primary HIV 
infection. Unprotected anal (less commonly oral) inter-
course remains the primary route for transmission.10 
Most heterosexual patients with HIV in the United 
Kingdom have contracted the disease abroad, mostly in 
sub-Saharan Africa.10 However, the number of people 
infected heterosexually in the UK is increasing. Trans-
mission through injecting drug use and mother to child 
transmission have remained low since the start of the 
epidemic.2
 EASILY MISSED?  
 Primary HIV infection 
 Gautam  Das ,  Piero  Baglioni ,  Onyebuchi  Okosieme 
 Prince Charles Hospital, Gurnos, 
Merthyr Tydfil CF47 9DT 
 Correspondence to: G Das 
 drgdas@gmail.com 
 
Cite this as:  BMJ 2010;341:c4583 
 doi: 10.1136/bmj.c4583 
 This is one of a series of 
occasional articles highlighting 
conditions that may be more 
common than many doctors 
realise or may be missed at 
first presentation. The series 
advisers are Anthony Harnden, 
university lecturer in general 
practice, Department of Primary 
Health Care, University of Oxford, 
and Richard Lehman, general 
practitioner, Banbury. If you 
would like to suggest a topic 
for this series please email us 
(easilymissed.bmj@bmjgroup.
com). 
 CASE SCENARIO 
 A previously healthy 19 year old man was admitted to 
our medical ward with a history of fever, sore throat, 
and a maculopapular rash on his trunk. An upper 
respiratory tract infection had been diagnosed in the 
community a few days before. A monospot test (for 
infectious mononucleosis caused by Epstein-Barr 
virus) was negative, and he initially denied risky 
sexual behaviour and declined an offer of HIV testing. 
His symptoms improved, but before discharge he 
mentioned to the ward sister that he had had a casual 
sexual encounter with a man a few weeks earlier. He 
then consented to an HIV test, which was positive for 
the p24 antigen. 
 HOW COMMON IS PRIMARY HIV INFECTION? 2  
 Symptoms are present in 50-90% of individuals with primary 
HIV infection 1 
 During 2008 there were 7298 new diagnoses of HIV in the 
United Kingdom. In the same year, 27% of the estimated 
83 000 people with HIV were thought to be unaware of their 
infection  (because many people only realise they have HIV 
infection when they develop full blown AIDS)  
 The two groups with the highest HIV prevalence in the 
UK are men who have sex with men, and black African 
heterosexuals. The number of new infections acquired 
heterosexually increased by 53% (from 740 to 1130 cases) 
from 2004 to 2008 
 The estimated numbers of new infections acquired through 
injecting drug use and mother to child transmission (170 and 
110 cases respectively in 2008) have remained stable since 
the start of the epidemic 
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Investigations
By definition, primary HIV infection precedes seroconver-
sion, and therefore testing limited to viral  antibodies may 
initially convey negative or borderline results.1 The infec-
tion is characterised by a high plasma virus load, and direct 
testing for viral antigen (p24 antigen) or nucleic acid (HIV 
RNA) usually confirms the diagnosis (figure).1 Although 
p24 antigen testing is less sensitive than HIV RNA (88.7% 
v 100%), it is usually preferred in non-specialist settings 
because it is less expensive (£2 v £75 in our institution) and 
associated with fewer false positive results (100% v 97.4% 
specificity).11 
Nowadays testing for antibodies and p24 antigen can be 
carried out simultaneously, and clinicians should liaise with 
local laboratories about available tests. As highlighted in a 
recent statement by the  British  Association of Sexual Health 
and HIV (BASHH), patients presenting very early after onset 
of symptoms may still be missed by currently available tests. 
When such tests first give negative results, follow-up  testing 
is  recommended three months later.12  Antibodies are detect-
able three to 12 weeks after infection but may occasionally 
take as long as six to 12 months to appear.1 Pretest counsel-
ling does not usually need to be lengthy but should cover 
the benefits of testing and how the results will be conveyed. 
Written consent is also not routinely necessary as this may 
discourage the test by according it special status.9  
How is it managed?
After diagnosis, refer the patient immediately to a 
specialist for further investigation and management.9 
Results should be clearly communicated in person and 
in a confidential environment. Avoid detailed counsel-
ling after HIV testing but reassure the patient that their 
symptoms are temporary and do not reflect permanent 
immunosuppression and that the condition is treata-
ble.1  9 Also explore available support to the patient for 
coping with the diagnosis. Finally, discuss appropriate 
measures to prevent onward transmission of infection.
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KEY POINTS
Primary HIV infection should be suspected in people at 
risk of HIV who present with an acute viral illness
Diagnosis of primary HIV infection may reduce HIV 
transmission through modification of sexual risk 
behaviour and will allow monitoring for immune 
deficiency and timely institution of highly active 
antiretroviral treatment when indicated
First line testing comprises both HIV antibody and p24 
antigen levels 
If a patient declines testing, explore and document the 
reasons for this, correcting any inaccurate beliefsApproximate time course of viral and antibody changes during 
primary HIV infection 
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Symptoms
When I asked a patient attending the emergency 
department for his drug history he retrieved a paper 
from his pocket. It was the size of the relevant box on 
my clerking form and contained a typed list of his 23 
medications, complete with his name, date of birth, 
and hospital number. On its back was double sided 
tape so that I could attach it to the notes.
Camille Gajria senior house officer, St Mary’s Hospital, London 
mcgajria@gmail.com
Patient consent not required (patient anonymised, dead, or 
hypothetical).
Cite this as: BMJ 2010;341:c6249
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RATIONAL TESTING
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Richard Hughes
National Hospital for Neurology 
and Neurosurgery, London  
WC1N 3BG, UK
Correspondence to:  
rhughes11@btinternet.com
Cite this as: BMJ 2010;341:c6100
doi: 10.1136/bmj.c6100
This series of occasional articles 
provides an update on the best 
use of key diagnostic tests in the 
initial investigation of common or 
important clinical presentations. 
The series advisers are Steve 
Atkin, professor, head of 
department of academic 
endocrinology, diabetes, and 
metabolism, Hull York Medical 
School; and Eric Kilpatrick, 
honorary professor, department 
of clinical biochemistry, Hull 
Royal Infirmary, Hull York Medical 
School.
A 65 year old woman presented with gradual onset of burn-
ing pain and loss of feeling in her toes spreading up to her 
ankles over three months. She had no family history of simi-
lar illness and no known other disease. She drank only the 
occasional glass of wine, and had not been exposed to any 
drugs or known toxins. Examination was normal except 
that she had a body mass index of 32, absent ankle reflexes; 
absent flexor plantar responses; and reduced pinprick, light 
touch, and vibration sensation in her toes.
What is the next investigation?
The clinical picture points to a diagnosis of a distal sym-
metrical polyneuropathy of large myelinated nerve fibres 
(causing numbness, impaired light touch and vibration 
sensation, and loss of ankle reflexes) and small myelinated 
and unmyelinated nerve fibres (causing pain and impaired 
pain sensation). Similar symptoms could be caused by a 
myelopathy, but the absent ankle reflexes and flexor plantar 
responses rule this out. Cauda equina lesions would prob-
ably cause back pain and sphincter problems, which were 
not present.
The investigations should be guided by the  clinical  picture. 
Questioning had already made hereditary  neuropathy and 
neuropathy related to alcohol, drugs, and toxins unlikely. 
Toxins, apart from alcohol, are now rare causes, but arsenic 
and organic solvents need to be considered. Many drugs can 
cause peripheral neuropathy (box), so check the side effects 
of any drug that the patient is taking.
Polyneuropathy may arise in the course of many  illnesses, 
particularly diabetes. Table 1 lists other common causes. 
Thus, in a general practice setting, initial testing would rea-
sonably include the blood tests listed in table 2.
Unless the cause can be identified and treated, the patient 
will need immediate specialist referral. Two of the most com-
mon and easily treated causes, diabetes and alcohol misuse, 
can often be identified and  managed in primary care. Always 
refer patients with severe symptoms, rapidly progressive dis-
ease, or additional motor symptoms. Further testing should 
include nerve  conduction studies to identify whether the 
neuropathy is purely sensory or also affects motor nerve 
fibres, and whether the primary pathology is axonal (causing 
dying back of axons) or demyelinating (affecting Schwann 
cells and myelin sheaths). Most  neuropathies, especially 
distal symmetrical sensory neuropathies, are axonal. The 
causes of demyelinating neuropathy are more  limited and 
more likely to be inflammatory and treatable.  Paraneoplastic 
neuropathy is uncommon but a concern with recent onset 
neuropathy, and the possibility of an underlying  neoplasm—
especially a small cell lung carcinoma—should not be for-
gotten. Many other systemic diseases—such as sarcoidosis, 
Sjögren’s syndrome, and the vasculitides—can cause a pain-
ful symmetrical distal sensory neuropathy, but in these dis-
eases an  asymmetrical picture of multiple mononeuropathy 
is more typical.5
Outcome
Fasting blood glucose, full blood count, erythrocyte 
 sedimentation rate, liver and renal function, serum 
 immunofixation electrophoresis, and concentrations of 
thyroid stimulating hormone were all normal and her 
serum vitamin B-12 concentration was low normal. She 
was referred to a neurologist, and nerve conduction tests 
showed reduced sensory action potentials, normal motor 
nerve conduction consistent with a sensory axonal neu-
ropathy, and no evidence of demyelination. A glucose 
tolerance test showed impaired glucose tolerance but not 
diabetes, borderline serum cholesterol, and raised triglycer-
ides. Further investigations including tests for  antineuronal 
antibodies, which are present in about half of people with 
paraneoplastic neuropathy, and chest  radiography were 
negative. Because she had no family history or other 
 features of a hereditary neuropathy, genetic testing was 
not performed. Serum methylmalonic acid, a vitamin B-12 
LEARNING POINTS
Diabetes, alcohol misuse, and HIV infection are the most 
common causes of distal symmetrical sensory neuropathy
Also consider vitamin B-12 deficiency, uraemia, 
paraproteinaemia, and hypothyroidism 
If the cause and management are obvious, as in diabetes 
or alcohol misuse, specialist referral may be avoided. 
Red flags for referral to a neurologist are uncertain cause, 
severe symptoms, rapid progression, and weakness
Chronic idiopathic axonal polyneuropathy is a diagnosis of 
exclusion, with uncertain prevalence (10-40% of hospital 
series of chronic axonal polyneuropathy) and possible 
association with impaired glucose tolerance or metabolic 
syndrome
Table 1 | Most common causes of symmetrical neuropathy
Disease Prevalence
Diabetes1 2 11-41% (depending on duration, type, 
and control of diabetes)
Paraproteinaemia2 3 9-10%
Alcohol misuse1 7%
Renal failure1 4%
Vitamin B-12 deficiency1 3.6%
HIV infection1 16%, but depends on the population 
studied and is usually much lower
Chronic idiopathic axonal 
neuropathy4
10-40% of different hospital series
The investigation of the cause of 
symmetrical polyneuropathy should 
be guided by careful history taking and 
examination
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metabolite, was measured, because her previous B-12 
value was in the low normal range, but the result was nor-
mal. In one series, 12 of 27 patients with polyneuropathy 
and B-12 deficiency had the diagnosis made on the basis 
of abnormal metabolites.6 Lumbar puncture was not per-
formed. Examination of cerebrospinal fluid is not helpful 
in the diagnosis of chronic axonal neuropathies, although 
cerebrospinal fluid protein concentrations are often high 
in demyelinating neuropathy.2 Because the patient had no 
asymmetry or evidence of inflammation, nerve biopsy was 
not performed. Insufficient data are available on whether 
nerve biopsy can help in the diagnosis of chronic symmetri-
cal sensory polyneuropathy.7 Biopsy carries a slight risk of 
wound infection with delayed healing and, albeit rarely, 
persistent neuropathic pain.8 A diagnosis of chronic idi-
opathic axonal neuropathy was made by exclusion. The 
patient was advised about foot care, weight reduction, 
exercise, and maintaining as active a lifestyle as possible. 
She was monitored for the development of diabetes and the 
management of hypertriglyceridaemia.
The cause of chronic idiopathic axonal polyneuropathy 
is not understood and is probably heterogeneous. In some 
patients it may be related to the metabolic syndrome because 
impaired glucose tolerance has been found in 25-36% of 
patients—about twice as often as in controls.2 One study 
found a closer association with hypertriglyceridaemia, a fea-
ture of the metabolic syndrome, than with impaired glucose 
tolerance.4 The condition is slowly progressive, with increas-
ing difficulty in walking and often persistent neuropathic 
pain. Systematic reviews have provided evidence for short 
term benefit from amitriptyline, pregabalin, duloxetine, and 
tramadol for pain, but in the long term patients often manage 
their symptoms without drugs because of adverse side effects.
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Drugs that cause peripheral neuropathy
Amiodarone
Bortezomib
Chloroquine
Dapsone
Disulfiram
Ethambutol
Gold
Isoniazid
Metronidazole
Misonidazole
Nitrofurantoin
Nitrous oxide (with a myelopathy)
Nucleoside analogue reverse transcriptase inhibitors: 
zalcitabine, didanosine, and stavudine
Phenytoin
Platinum: cisplatin and carboplatin
Podophyllin
Pyridoxine
Suramin
Taxanes: paclitaxel and docetaxel
Thalidomide
Vincristine
Table 2 | Initial investigations of symmetrical neuropathy
Test Detects
Fasting blood glucose Diabetes 
Liver function Occult alcohol misuse; systemic 
disease
Full blood count Occult alcohol misuse; systemic 
disease
Erythrocyte sedimentation rate Systemic disease
Serum creatinine Renal failure
Thyroid stimulating hormone 
concentration
Myxoedema
Serum protein immunofixation 
electrophoresis 
Serum paraprotein
Vitamin B-12 Vitamin B-12 deficiency
HIV serology (in at risk patients) HIV infection
A hospital patient being anticoagulated asked what 
things interacted with warfarin. I named a few 
medications and ended by saying, “oh, and cranberry 
juice of course.” 
The patient confessed to having drunk cranberry 
juice the day before, although the patient didn’t 
normally drink it. On asking if a visitor had brought it 
in, I was surprised to learn that it had come with the 
hospital meal: “I just ticked the option for fruit juice, 
and yesterday’s juice was cranberry.”
Luckily this was of no consequence for the patient, 
who went on to be discharged uneventfully. Although 
the current literature is calling into question the inter-
action between coumarins and cranberry products, 
perhaps we should err on the side of caution and not 
supply cranberry juice to hospital inpatients until a 
definitive answer is known.
Peter Lawrence Zaki Labib foundation year 1 doctor, London
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Food (and cranberry juice)  
for thought
